Shutterstock
Up to now, the sheer amount of work required in bringing intelligent automation systems up to speed and validating them for life sciences R&D purposes, e.g. to transform adverse event case intake, has threatened to undermine the business case. But now the large language models (LLMs) used to power Generative AI are bringing down those barriers and bolstering compliance. The opportunity surrounds on-the-fly data discovery, ‘in context’ learning, and narrative extrapolation – in a way that’s ‘explainable’ to regulators. Ramesh Ramani and RaviKanth Valigari, AI experts at ArisGlobal, explore what’s possible.